REGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $38.00.

Several equities analysts have recently issued reports on RGNX shares. SVB Leerink upgraded REGENXBIO from a "market perform" rating to an "outperform" rating and set a $37.00 price target on the stock in a research note on Wednesday, March 6th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Wednesday. Chardan Capital reiterated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 7th. Barclays lifted their price target on REGENXBIO from $45.00 to $55.00 and gave the company an "overweight" rating in a research note on Thursday, March 7th. Finally, Robert W. Baird lifted their price target on REGENXBIO from $34.00 to $39.00 and gave the company an "outperform" rating in a research note on Wednesday, March 6th.

REGENXBIO Trading Up 0.1 %

NASDAQ RGNX traded up $0.02 during midday trading on Friday, hitting $19.17. The company had a trading volume of 424,324 shares, compared to its average volume of 646,857. The company has a market capitalization of $851.72 million, a PE ratio of -3.18 and a beta of 1.29. The firm has a 50-day moving average price of $19.15 and a 200-day moving average price of $17.79. REGENXBIO has a twelve month low of $11.83 and a twelve month high of $28.80.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.16). The company had revenue of $22.30 million during the quarter, compared to analyst estimates of $34.01 million. REGENXBIO had a negative net margin of 291.99% and a negative return on equity of 68.18%. REGENXBIO's revenue was down 28.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.38) earnings per share. On average, equities analysts anticipate that REGENXBIO will post -3.98 EPS for the current year.

Insider Buying and Selling

In other REGENXBIO news, insider Steve Pakola sold 12,878 shares of REGENXBIO stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $28.36, for a total transaction of $365,220.08. Following the transaction, the insider now directly owns 107,192 shares of the company's stock, valued at approximately $3,039,965.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other REGENXBIO news, CEO Kenneth T. Mills sold 15,000 shares of REGENXBIO stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $16.76, for a total transaction of $251,400.00. Following the transaction, the chief executive officer now directly owns 408,035 shares of the company's stock, valued at approximately $6,838,666.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steve Pakola sold 12,878 shares of REGENXBIO stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $28.36, for a total value of $365,220.08. Following the transaction, the insider now directly owns 107,192 shares in the company, valued at $3,039,965.12. The disclosure for this sale can be found here. Insiders have sold 87,878 shares of company stock worth $1,627,620 in the last 90 days. Insiders own 12.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Napatree Capital LLC acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $720,000. PNC Financial Services Group Inc. lifted its stake in shares of REGENXBIO by 73.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 746 shares during the period. Vanguard Group Inc. lifted its stake in shares of REGENXBIO by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 4,440,838 shares of the biotechnology company's stock valued at $79,713,000 after purchasing an additional 64,265 shares during the period. Wellington Management Group LLP acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $692,000. Finally, Virtu Financial LLC acquired a new position in shares of REGENXBIO in the 4th quarter valued at about $377,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.